AUG 04, 2020 4:27 PM PDT

Erectile Dysfunction Drug Cures Critical COVID-19 Patients

WRITTEN BY: Annie Lennon

Critically ill patients who received COVID-19 drug candidate aviptadil (RLF-100) were able to make a rapid recovery from respiratory failure from COVID-19, according to pharmaceutical companies NeuroRX and Relief Therapeutics.

Typically used alongside phentolamine to treat erectile dysfunction, the first report on the drug's success comes from doctors in Houston Methodist Hospital. 

Although these early results are yet to be released, the report highlights the case of a 54-year-old man who contracted COVID-19 while receiving treatment for rejection of a double lung transplant. Within four days of treatment with RLF-100, he reportedly came off the ventilator. The companies say that similar results also came for 15 other patients treated under emergency use. 

More than this, the report supposedly highlights the rapid clearance of classic pneumonitis findings on x-rays, improved blood oxygen, and a 50% or greater average reduction in laboratory markers for inflammation by COVID-19. 

An independent research team at the Oswaldo Cruz Foundation in Rio de Janeiro, Brazil, also showed that the drug candidate was able to prevent SARS coronavirus replication in human lung cells and monocytes in Petri dishes. 

Although promising results, due to the relatively small sample size, and other limitations, Jonathon Javitt, NeuroRx CEO and Chairman remains cautious. 

"If you ask me whether this is the cure to COVID, my answer is that I don't know, but it shows promise, and I hope so," says Javitt. "Of course, this is a small number [refering to patient data so far], and of course, testing that includes patients given placebos is needed."

Last week, the US Food and Drug Administration granted the drug an Expanded Access Protocol to treat respiratory distress from COVID-19. This means that the drug can be administered on an emergency basis to patients who are too ill to join a clinical trial and pregnant women. Meanwhile, Phase II/III trials involving 70 people are still ongoing. 

 

Sources: Clinical Trial ArenaTimes of Israel

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
JUL 28, 2022
Cannabis Sciences
Are Cannabis Users Nicer?
JUL 28, 2022
Are Cannabis Users Nicer?
A study published in Nature offers evidence that cannabis has a positive effect on the psychosocial health of young adul ...
JUL 23, 2022
Drug Discovery & Development
Antibiotics Affect Gut Microbiome of Male and Female Rats Differently
JUL 23, 2022
Antibiotics Affect Gut Microbiome of Male and Female Rats Differently
Antibiotics induce sex-specific effects on the gut microbiome of male and female rats. The corresponding study was publi ...
JUL 23, 2022
Drug Discovery & Development
No Evidence for Depression and Serotonin Activity Link
JUL 23, 2022
No Evidence for Depression and Serotonin Activity Link
A new review study found that there is no clear evidence that serotonin levels or serotonin activity are responsible for ...
SEP 04, 2022
Drug Discovery & Development
Deep Brain Stimulation Shows Promise for Binge-Eating Disorder
SEP 04, 2022
Deep Brain Stimulation Shows Promise for Binge-Eating Disorder
Deep brain stimulation (DBS) may help control symptoms of binge-eating disorder and induce weight loss. The correspondin ...
SEP 29, 2022
Neuroscience
Omega 3's Increase Attention, Reduce Impulsivity in Teenagers
SEP 29, 2022
Omega 3's Increase Attention, Reduce Impulsivity in Teenagers
Omega-3 fatty acids from fish are linked to greater selective and sustained attention in teenagers, while omega 3’ ...
OCT 03, 2022
Clinical & Molecular DX
Could Blood Samples Detect the Risk of Peripheral Neuropathy in Type 2 Diabetes?
OCT 03, 2022
Could Blood Samples Detect the Risk of Peripheral Neuropathy in Type 2 Diabetes?
Type 2 diabetes is a disease that impacts the body’s ability to respond to insulin. Insulin is a hormone made by t ...
Loading Comments...